The Differential Effects of Diabetes Therapy on Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

17 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-05-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine if different diabetes treatments have different effects on inflammation; in particular, kidney inflammation. This type of inflammation is common in people with diabetes, and can lead to kidney failure. This study will investigate the effect of different types of diabetes treatment on kidney inflammation. This will help us to decide if certain types of medicine should be preferred in people with evidence of inflammation in their kidneys, as this may help prevent major complications including kidney failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

NCT01847313

Diabetic Kidney Disease

COMPLETED PHASE3

Renal Impairment in Type 2 Diabetic Subjects

NCT00554450

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

NCT06820567

Chronic Kidney Diseases Diabetes Type 2

NOT_YET_RECRUITING PHASE3

A Study in Participants With Diabetic Kidney Disease

NCT01113801

Diabetic Kidney Disease Diabetic Nephropathy Diabetic Glomerulosclerosis

TERMINATED PHASE2

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT01847092

Chronic Kidney Disease Type 2 Diabetes Mellitus

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this prospective cohort study, patients who are clinically determined to require escalation of their glycaemic therapy, and prescribed a DPP4 inhibitor, GLP-1 receptor agonist, or insulin, will be invited to participate.

Blood and urine samples will be taken before, 4 to 8 weeks after, and 26 weeks after starting the new therapy. Markers of inflammation, renal function and glycemic control will be measured at each timepoint.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Nephropathy Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dipeptidyl-Peptidase IV Inhibitors

Newly started on DPP4 inhibitor for hyperglycaemia

Dipeptidyl-Peptidase IV Inhibitors

Intervention Type DRUG

Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia

Glucagon-Like Peptide 1

Newly started on GLP-1 for hyperglycaemia or obesity

Glucagon-Like Peptide 1

Intervention Type DRUG

Glucagon-Like Peptide 1 to treat hyperglycaemia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dipeptidyl-Peptidase IV Inhibitors

Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia

Intervention Type DRUG

Glucagon-Like Peptide 1

Glucagon-Like Peptide 1 to treat hyperglycaemia

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DPP4 inhibitors Liraglutide Exenatide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 30 years
* Diagnosis of type 2 diabetes for one year or more
* Diagnosis of DKD as defined by two distinct albumin:creatinine ratio measurements above the gender specific range in the local reference laboratory with an interval of no less than eight week between measurements
* Stable dose of an inhibitor of the renin angiotensin system for a period of 8 weeks

Exclusion Criteria

* Any cognitive impediment that preclude the participant from giving free and informed consent
* Substance abuse including alcohol excess
* Use of a GLP-1 analogue in the last 6 months
* Pregnancy
* Hypersensitivity to the prescribed treatment

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No